Table IV.
Subgroup analysis of matched baseline characteristics and outcomes
| Characteristics | After propensity matching |
|||||
|---|---|---|---|---|---|---|
| TNFi (n = 101) | No TNFi (n = 101) | P value | MTX (n = 128) | No MTX (n = 128) | P value | |
| Demographics | ||||||
| Age at index, y ± SD | 49.7 ± 15.7 | 52.0 ± 18.5 | .3304 | 58.7 ± 14.9 | 58.7 ± 16.7 | .9968 |
| Female, n (%) | 61 (60.4) | 67 (66.3) | .3809 | 94 (73.4) | 94 (73.4) | .8880 |
| White, n (%) | 46 (45.5) | 48 (47.5) | .7779 | 53 (41.4) | 53 (41.4) | 1.0000 |
| Comorbidities, n (%) | ||||||
| Diseases of the digestive system | 50 (49.5) | 51 (50.5) | .8881 | 62 (48.4) | 62 (48.4) | 1.0000 |
| Diseases of the musculoskeletal system and connective tissue | 57 (56.4) | 59 (58.4) | .7760 | 98 (76.6) | 99 (77.3) | .8820 |
| Diseases of the nervous system | 37 (36.6) | 34 (33.7) | .6584 | 63 (49.2) | 55 (43.0) | .3158 |
| Diseases of the blood and blood-forming organs | 36 (35.6) | 35 (34.7) | .8828 | 58 (45.3) | 53 (41.4) | .5283 |
| Diseases of the circulatory system | 49 (48.5) | 44 (43.6) | .4803 | 88 (68.8) | 96 (75.0) | .2661 |
| Diseases of the skin and subcutaneous tissue | 27 (26.7) | 27 (26.7) | 1.0000 | 36 (28.1) | 32 (25) | .5714 |
| Diabetes mellitus | 11 (10.9) | N/A∗ | — | 33 (25.8) | 32 (25) | .8858 |
| Body mass index 30-39.9 kg/m2 | 18 (17.8) | 12 (11.9) | .2352 | 25 (19.5) | 24 (18.8) | .8738 |
| 45-day outcomes, n (%) | ||||||
| Hospitalization | 24 (23.8) | 33 (32.7) | .1594 | 40 (31.3) | 46 (35.9) | .4272 |
| Death | N/A∗ | N/A∗ | — | 12 (9.4) | N/A∗ | — |
MTX, Methotrexate; N/A, not available; SD, standard deviation; TNFi, tumor necrosis factor inhibitor.
∗
TriNetX obfuscates patient counts ≤10 to safeguard protected health information.